| 货号 | 15035-10mg |
| 描述 | Cilostazol is a quinolinone derivative first developed as an anti-thrombotic agent, inhibiting ADP-dependent platelet aggregation.1 This is mediated by selective and specific inhibition of cyclic nucleotide phosphodiesterase 3 (IC50 = 200 nM).2 Because of its effects on platelets, cilostazol is useful in various conditions, including peripheral artery disease, stroke, and post-stent stenosis.2,3,4 It is metabolized to products which also affect platelet aggregation by cytochrome P450 (CYP) isoforms CYP3A4, CYP3A5, and CYP1B1.5 |
| 别名 | OPC 21;OPC 13013;Pletaal;Pletal; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Koga, Y.,Kihara, Y.,Okada, M., et al. 2(1H)-Quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities. Bioorganic & Medicinal Chemistry Letters 8(12), 1471-1476 (1998). 2.Rondina, M.T. and Weyrich, A.S. Targeting phosphodiesterases in anti-platelet therapy. Handb.Exp.Pharmacol. 210, 225-238 (2012). 3.DiNicolantonio, J.J.,Lavie, C.J.,Fares, H., et al. Meta-analysis of Cilostazol versus Aspirin for the secondary prevention of stroke. American Journal of Cardiology 9149(13), 1292-1297 (2013). 4.Au, T.B.,Golledge, J.,Walker, P.J., et al. Peripheral arterial disease - diagnosis and management in general practice. Aust.Fam.Physician 42(6), 397-400 (2013). 5.Hiratsuka, M.,Hinai, Y.,Sasaki, T., et al. Characterization of human cytochrome P450 enzymes involved in the metabolism of cilostazol. Drug Metabolism and Disposition 35(10), 1730-1732 (2007). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 369.5 |
| 分子式 | C20H27N5O2 |
| CAS号 | 73963-72-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |